Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study

Several studies have shown that the combination of Iparomlimab, Tuvonralimab, and Bevacizumab exhibits potent anti-tumor activity and favorable safety in various solid tumors, including liver cancer. However, the efficacy and safety of this regimen in melanoma patients with acquired resistance to immunotherapy remain unexplored and require further validation. This study aims to evaluate the efficacy and safety of the Iparomlimab, Tuvonralimab, and Bevacizumab combination in patients with immune-resistant melanoma. Furthermore, it will analyze and compare treatment responses among different melanoma subtypes to identify optimal treatment strategies for clinical practice.

NCT Number	NCT07004335
Lead Sponsor	Hebei Medical University Fourth Hospital Collaborators: Qilu Pharmaceutical Co., Ltd.
Conditions	PD-(L)1, CTLA-4, Advanced Melanoma, Iparomlimab, Tuvonralimab, Bevacizumab
Enrollment	40 participants
Start Date	2025-07-01
Primary Completion	2028-12-31 (estimated)
Study Completion	2029-01-31 (estimated)
Updated on ClinicalTrials.gov	2025-06-04